Grave's Eye Disease Developing Following Radioiodine Treatment for Toxic Nodular Goitre

Abstract

The development of Grave's ophthalmopathy (GO) following radioiodine (RI) treatment for Grave's thyrotoxicosis, though controversial, is well described. The development of ophthalmopathy following RI treatment for toxic nodular goitre is much less recognised. We report a 49 year-old female patient who developed thyrotoxicosis and GO after receiving RI treatment for toxic nodular goitre and we also review the relevant literature.

Key words

Toxic nodular goitre - grave's disease - grave's ophthalmopathy - radioiodine

References

• 1 Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy.  N Engl J Med. 1998;  338 73-78
• 2 Chiovato L, Santini F, Vitti P, Bendinelli G, Pinchera A. Appearance of thyroid stimulating antibody and Graves’ disease after radioiodine therapy for toxic nodular goitre.  Clin Endocrinol (Oxf). 1994;  40 803-806
• 3 Cseke B, Balazs C. Development of Basedow disease after radioiodine therapy for nodular goiter.  Orv Hetil. 2003;  144 2327-2329
• 4 Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell’Unto E, Mazzi B, Rocchi R, Barbesino G, Pinchera A. Graves’ ophthalmopathy and 131I therapy.  Q J Nucl Med. 1999;  43 307-312
• 5 Nygaard B, Faber J, Veje A, Hegedus L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.  Thyroid. 1999a;  9 477-481
• 6 Nygaard B, Metcalfe RA, Phipps J, Weetman AP, Hegedus L. Graves’ disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter.  J Endocrinol Invest. 1999b;  22 481-485
• 7 Orsolon P, Lupi A, Antoni De, Migliorati G, Vianello, Dri A. Appearance of Graves’-like disease following regression of autonomously functioning thyroid nodules. Two case reports.  Minerva Endocrinol. 1998;  23 53-56
• 8 Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays.  Clin Endocrinol (Oxf). 2001;  55 381-390
• 9 Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy.  J Clin Endocrinol Metab. 2005;  90 5321-5323
• 10 Rasmussen AK, Nygaard B, Feldt-Rasmussen U. (131)I and thyroid-associated ophthalmopathy.  Eur J Endocrinol. 2000;  143 155-160
• 11 Smyth PP, Neylan D, O’Donovan DK. The prevalence of thyroid-stimulating antibodies in goitrous disease assessed by cytochemical section bioassay.  J Clin Endocrinol Metab. 1982;  54 357-361
• 12 Leussen JJ van, Edelbroek MA, Talsma MA, Heide LJ de. Graves’ disease induced by Na(131)I therapy for toxic multinodular goitre.  Neth J Med. 2000;  57 194-197
• 13 Wallaschofski H, Kuwert T, Lohmann T. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves’ disease and toxic multinodular goitre.  Exp Clin Endocrinol Diabetes. 2004;  112 171-174
• 14 Wallaschofski H, Muller D, Georgi P, Paschke R. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment.  Horm Metab Res. 2002;  34 36-39
• 15 Wallaschofski H, Orda C, Georgi P, Miehle K, Paschke R. Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter.  Horm Metab Res. 2001;  33 504-507

Correspondence